Free Trial
NASDAQ:IART

Integra LifeSciences (IART) Stock Price, News & Analysis

Integra LifeSciences logo
$13.05 +0.05 (+0.38%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$13.07 +0.02 (+0.18%)
As of 08:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Integra LifeSciences Stock (NASDAQ:IART)

Key Stats

Today's Range
$12.59
$13.31
50-Day Range
$11.60
$16.85
52-Week Range
$11.06
$32.66
Volume
673,072 shs
Average Volume
966,491 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.63
Consensus Rating
Reduce

Company Overview

Integra LifeSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

IART MarketRank™: 

Integra LifeSciences scored higher than 81% of companies evaluated by MarketBeat, and ranked 195th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Integra LifeSciences has received a consensus rating of Reduce. The company's average rating score is 1.78, and is based on 2 buy ratings, 3 hold ratings, and 4 sell ratings.

  • Amount of Analyst Coverage

    Integra LifeSciences has only been the subject of 4 research reports in the past 90 days.

  • Read more about Integra LifeSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Integra LifeSciences are expected to grow by 2.04% in the coming year, from $2.45 to $2.50 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Integra LifeSciences is -34.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Integra LifeSciences is -34.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Integra LifeSciences has a PEG Ratio of 0.73. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Integra LifeSciences has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Integra LifeSciences' valuation and earnings.
  • Percentage of Shares Shorted

    9.33% of the float of Integra LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Integra LifeSciences has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Integra LifeSciences has recently increased by 13.75%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Integra LifeSciences does not currently pay a dividend.

  • Dividend Growth

    Integra LifeSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.33% of the float of Integra LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Integra LifeSciences has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Integra LifeSciences has recently increased by 13.75%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Integra LifeSciences has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Integra LifeSciences this week, compared to 5 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Integra LifeSciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.54% of the stock of Integra LifeSciences is held by insiders.

  • Percentage Held by Institutions

    84.78% of the stock of Integra LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Integra LifeSciences' insider trading history.
Receive IART Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

IART Stock News Headlines

Integra LifeSciences: Struggling, Yet Getting Cheap
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

IART Stock Analysis - Frequently Asked Questions

Integra LifeSciences' stock was trading at $22.68 at the beginning of the year. Since then, IART shares have decreased by 42.5% and is now trading at $13.05.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) issued its earnings results on Monday, May, 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.43 by $0.02. The business's quarterly revenue was up 3.7% compared to the same quarter last year.
Read the conference call transcript
.

Shares of Integra LifeSciences split before market open on Tuesday, January 3rd 2017.The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were payable to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Integra LifeSciences subsidiaries include these companies: ACell Inc, Rebound Therapeutics, Arkis BioSciences, Codman Neuro, TGX Medical Systems, Derma Sciences, Tekmed Instruments S.p.A, and more.

Top institutional investors of Integra LifeSciences include MassMutual Private Wealth & Trust FSB (0.01%). Insiders that own company stock include Stuart Essig, Michael J Mcbreen, Raymond G Murphy, Lisa Evoli, Witte Jan De and Jeffrey Mosebrook.
View institutional ownership trends
.

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Integra LifeSciences investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Tesla (TSLA) and Home Depot (HD).

Company Calendar

Last Earnings
5/05/2025
Today
7/10/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IART
CIK
917520
Employees
4,396
Year Founded
1989

Price Target and Rating

High Price Target
$25.00
Low Price Target
$12.00
Potential Upside/Downside
+42.7%
Consensus Rating
Reduce
Rating Score (0-4)
1.78
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
5.33
P/E Growth
0.73
Net Income
-$6.94 million
Pretax Margin
-2.65%

Debt

Sales & Book Value

Annual Sales
$1.61 billion
Cash Flow
$4.47 per share
Price / Cash Flow
2.92
Book Value
$20.03 per share
Price / Book
0.65

Miscellaneous

Free Float
74,961,000
Market Cap
$1.01 billion
Optionable
Optionable
Beta
1.15

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:IART) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners